- Home
- VMD vs LUNG Comparison
VMD vs LUNG Comparison
Compare VMD & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- LUNG
- Stock Information
- Founded
- VMD 2006
- LUNG 1995
- Country
- VMD United States
- LUNG United States
- Employees
- VMD N/A
- LUNG N/A
- Industry
- VMD
- LUNG Industrial Specialties
- Sector
- VMD
- LUNG Health Care
- Exchange
- VMD Nasdaq
- LUNG Nasdaq
- Market Cap
- VMD 273.5M
- LUNG 124.0M
- IPO Year
- VMD N/A
- LUNG 2020
- Fundamental
- Price
- VMD $7.00
- LUNG $2.77
- Analyst Decision
- VMD
- LUNG Buy
- Analyst Count
- VMD 0
- LUNG 6
- Target Price
- VMD N/A
- LUNG $11.53
- AVG Volume (30 Days)
- VMD 202.1K
- LUNG 261.1K
- Earning Date
- VMD 08-06-2025
- LUNG 07-30-2025
- Dividend Yield
- VMD N/A
- LUNG N/A
- EPS Growth
- VMD 19.95
- LUNG N/A
- EPS
- VMD 0.30
- LUNG N/A
- Revenue
- VMD $232,793,000.00
- LUNG $87,473,000.00
- Revenue This Year
- VMD $17.35
- LUNG $18.02
- Revenue Next Year
- VMD $12.87
- LUNG $18.17
- P/E Ratio
- VMD $23.32
- LUNG N/A
- Revenue Growth
- VMD 19.97
- LUNG 19.84
- 52 Week Low
- VMD $6.14
- LUNG $2.50
- 52 Week High
- VMD $9.81
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- VMD 55.77
- LUNG 43.44
- Support Level
- VMD $6.86
- LUNG $2.62
- Resistance Level
- VMD $7.25
- LUNG $2.88
- Average True Range (ATR)
- VMD 0.21
- LUNG 0.17
- MACD
- VMD 0.02
- LUNG 0.05
- Stochastic Oscillator
- VMD 67.14
- LUNG 71.37
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.